Relmada Therapeutics Announces $100 Million Underwritten Offering

Lowenstein Sandler has advised Relmada Therapeutics. Holland & Hart has advised the book-running managers. Relmada Therapeutics, a clinical-stage biotechnology company listed on Nasdaq under the symbol…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here
  Share:
Laura Testa

Author: Laura Testa

…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here